Bioleaders Corporation Net Assets
Bioleaders Corporation net assets. Based on the latest financial reports, Bioleaders Corporation (142760) has net assets worth ₩24.19 Billion KRW (≈ $16.39 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩32.47 Billion ≈ $22.01 Million USD) and total liabilities (₩8.29 Billion ≈ $5.62 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Bioleaders Corporation to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩24.19 Billion |
| % of Total Assets | 74.48% |
| Annual Growth Rate | 18.59% |
| 5-Year Change | -32.25% |
| 10-Year Change | 75.04% |
| Growth Volatility | 74.04 |
Net Assets of Bioleaders Corporation (2015–2025)
Net assets of Bioleaders Corporation from 2015 to 2025. This chart illustrates how Bioleaders Corporation's net assets have evolved over time, based on quarterly financial data. See Bioleaders Corporation (142760) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Bioleaders Corporation (2015–2025)
The table below shows the annual net assets of Bioleaders Corporation from 2015 to 2025. For live market cap and overall valuation, see Bioleaders Corporation market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩30.57 Billion ≈ $20.71 Million |
-18.07% |
| 2024-12-31 | ₩37.31 Billion ≈ $25.28 Million |
+4.22% |
| 2023-12-31 | ₩35.79 Billion ≈ $24.26 Million |
+65.05% |
| 2022-12-31 | ₩21.69 Billion ≈ $14.70 Million |
-51.93% |
| 2021-12-31 | ₩45.11 Billion ≈ $30.57 Million |
+47.41% |
| 2020-12-31 | ₩30.60 Billion ≈ $20.74 Million |
+28.49% |
| 2019-12-31 | ₩23.82 Billion ≈ $16.14 Million |
+1.36% |
| 2018-12-31 | ₩23.50 Billion ≈ $15.92 Million |
-33.18% |
| 2017-12-31 | ₩35.17 Billion ≈ $23.83 Million |
+101.38% |
| 2016-12-31 | ₩17.46 Billion ≈ $11.83 Million |
+214.49% |
| 2015-12-31 | ₩5.55 Billion ≈ $3.76 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bioleaders Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13401165843000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Bioleaders Corporation Net Assets Breakdown (December 2025)
Bioleaders Corporation net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩201.36 Billion | 658.78% |
| Total Equity | ₩30.57 Billion | 100.00% |
Bioleaders Corporation Competitors by Market Cap
The table below lists competitors of Bioleaders Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Redhill Biopharma Ltd
NASDAQ:RDHL
|
$2.53 Million |
|
Icon Energy Corp.
NASDAQ:ICON
|
$2.53 Million |
|
Banzai International Inc
NASDAQ:BNZI
|
$2.53 Million |
|
Cumulus Media Inc Class A
NASDAQ:CMLS
|
$2.54 Million |
|
Klondike Silver Corp
V:KS
|
$2.53 Million |
|
Chanson International Holding Class A Ordinary Shares
NASDAQ:CHSN
|
$2.53 Million |
|
TRU PRECIOUS METALS CORP.
F:706
|
$2.51 Million |
|
Power REIT
NYSE MKT:PW
|
$2.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioleaders Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 37,305,571,860 to 30,565,041,770, a change of -6,740,530,090 (-18.1%).
- Net loss of 13,051,157,000 reduced equity.
- Other factors increased equity by 6,310,626,910.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-13.05 Billion | -42.7% |
| Other Changes | ₩6.31 Billion | +20.65% |
| Total Change | ₩- | -18.07% |
Book Value vs Market Value Analysis
This analysis compares Bioleaders Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.12x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1234.18 | ₩177.00 | x |
| 2017-12-31 | ₩1930.51 | ₩177.00 | x |
| 2018-12-31 | ₩1285.57 | ₩177.00 | x |
| 2019-12-31 | ₩1176.11 | ₩177.00 | x |
| 2020-12-31 | ₩1116.42 | ₩177.00 | x |
| 2021-12-31 | ₩1574.19 | ₩177.00 | x |
| 2022-12-31 | ₩689.60 | ₩177.00 | x |
| 2023-12-31 | ₩1022.12 | ₩177.00 | x |
| 2024-12-31 | ₩988.62 | ₩177.00 | x |
| 2025-12-31 | ₩1449.71 | ₩177.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioleaders Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -116.36%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.39x
- Recent ROE (-42.70%) is above the historical average (-76.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -335.69% | -1260.95% | 0.15x | 1.72x | ₩-19.19 Billion |
| 2016 | -33.76% | -235.76% | 0.12x | 1.24x | ₩-7.64 Billion |
| 2017 | -18.90% | -87.38% | 0.20x | 1.07x | ₩-10.16 Billion |
| 2018 | -73.32% | -20.02% | 0.56x | 6.52x | ₩-19.58 Billion |
| 2019 | -117.75% | -38.48% | 0.49x | 6.22x | ₩-30.43 Billion |
| 2020 | -69.07% | -26.27% | 0.42x | 6.23x | ₩-24.20 Billion |
| 2021 | -43.82% | -19.54% | 0.54x | 4.19x | ₩-24.28 Billion |
| 2022 | -106.69% | -23.04% | 0.68x | 6.84x | ₩-25.31 Billion |
| 2023 | 24.28% | 43.90% | 0.37x | 1.49x | ₩4.71 Billion |
| 2024 | -18.75% | -44.75% | 0.25x | 1.67x | ₩-10.72 Billion |
| 2025 | -42.70% | -116.36% | 0.26x | 1.39x | ₩-16.11 Billion |
Industry Comparison
This section compares Bioleaders Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $287,302,015,827
- Average return on equity (ROE) among peers: -9.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioleaders Corporation (142760) | ₩24.19 Billion | -335.69% | 0.34x | $2.53 Million |
| ORIENTBIO Inc. (002630) | $62.29 Billion | 1.41% | 1.19x | $94.35 Million |
| Green Cross (005250) | $895.76 Billion | 3.06% | 4.14x | $285.63 Million |
| Green Cross Holdings Preference Shares (005257) | $1.67 Trillion | 10.22% | 0.94x | $2.85 Million |
| Pharmicell (005690) | $82.42 Billion | -31.18% | 0.21x | $361.91 Million |
| GeneOne Life Science Inc (011000) | $24.06 Billion | -31.66% | 1.13x | $32.81 Million |
| HLB Co. Ltd (028300) | $46.46 Billion | 0.00% | 0.75x | $3.66 Billion |
| Mgenplus Co. Ltd. (032790) | $11.48 Billion | -51.58% | 1.56x | $19.35 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $13.93 Million |
| Seoulin Bioscience Co.Ltd (038070) | $43.14 Billion | 6.18% | 0.41x | $21.71 Million |
| Hyundai Bioscience Co. Ltd (048410) | $14.17 Billion | 0.00% | 1.15x | $342.04 Million |
About Bioleaders Corporation
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and… Read more